Blood test may predict esophageal cancer treatment success

NCT ID NCT06979869

Recruiting now Knowledge-focused Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether changes in DNA markers in the blood can show how well esophageal cancer treatment is working. Researchers will compare these markers with standard CT/MRI scans and tumor markers. The goal is to find a simpler, less invasive way to track treatment response and guide therapy adjustments. 300 adults with esophageal cancer will participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma of esophagus esophageal cancer Esophageal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER

Contacts and locations

Locations

Cancer Hospital Affiliated to Shantou University Medical College
NOT_YET_RECRUITING

Shantou, Guangdong, China
Gansu Wuwei Cancer Hospital
RECRUITING

Wuwei, Gansu, China
General Hospital of Western Theater Command, People's Liberation Army (PLA)
RECRUITING

Chengdu, Sichuan, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, China
Tangdu Hospital
NOT_YET_RECRUITING

Xi'an, Shaanxi, China
The First Affiliated Hospital of Shanxi Medical University
NOT_YET_RECRUITING

Taiyuan, Shanxi, China
The First Affiliated Hospital of Yan'an University
NOT_YET_RECRUITING

Yan’an, Shaanxi, China
Xijing Hospital
RECRUITING

Xi'an, Shaanxi, China
Zhaoqing Gaoyao District People's Hospital
RECRUITING

Zhaoqing, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.